Tribeca Knowledge

NOVEMBER 28, 2023

T he drug-approval slump in major markets that clouded innovation prospects during 2022 seems to be over.

Food and Drug Administration 52

Food and Drug Administration Marketing FDA Prospecting 52

European Pharmaceutical Review

FEBRUARY 5, 2024

Incentivising small molecule drug innovation According to the Biotechnology Innovation Organization (BIO), the bipartisan Ensuring Pathways to Innovative Cures ( EPIC Act ) passed last week in the US, is a “critical” step for incentivising small molecule drug innovation.

Food and Drug Administration 97

Food and Drug Administration Medicine Food Pharmaceutical 97

Pharmaceutical Technology

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. It also boosts the drug’s safety, tolerability and efficacy.

Food and Drug Administration 98

Food and Drug Administration FDA Safety Food 98

European Pharmaceutical Review

NOVEMBER 25, 2022

The Luye Pharma drug demonstrated comparable bioavailability with Johnson and Johnson’s Invega Sustenna ® at steady state in a clinical trial ( NCT04922593 ). GlobalData’s report showed LY03010 is expected to launch in the US in 2024. If successful, the drug is forecasted to reach sales of $63.5 million in 2031, representing 0.6

Competition 105

Competition Food and Drug Administration Pharma Food 105

Clarivate

SEPTEMBER 11, 2024

Though there is no cure for the disease, people with Alzheimer’s can receive personalized, multimodal care and support to delay deterioration of their functional status and quality of life and alleviate the burden imposed on their care partners (Emblad, 2021; Bayly, 2021; Xiang, 2024). Currently, of the eight drugs approved by the U.S.

Food and Drug Administration 59

Food and Drug Administration Pharmacology Food FDA 59

European Pharmaceutical Review

OCTOBER 23, 2024

Donanemab was approved by the US Food and Drug Administration (FDA) as Kisunla (donanemab-azbt) in July 2024. This was followed by regulatory approval in Japan in September 2024. .” Results from the TRAILBLAZER-ALZ 2 study were published in the Journal of the American Medical Association (JAMA) in July 2023.

Food and Drug Administration 52

Food and Drug Administration Food Patients Medicine 52

European Pharmaceutical Review

JANUARY 25, 2024

Draft guidance published by the US Food and Drug Administration (FDA) in December 2023, discussed quality considerations for topical ophthalmic drug products, including key considerations for extractables and leachables (E&L) testing. This document is revised from a version published in October 2023.

FDA 98

FDA Food and Drug Administration Safety Manufacturing 98

European Pharmaceutical Review

MARCH 18, 2024

A Phase III trial has shown that compared oral drug delivery, administering levodopa through an infusion pump led to nearly two hours of day (1.72) of additional time in which the medicine reduced symptoms in Parkinson’s patients. Espay also stated that two additional subcutaneous delivery systems are also expected to be approved in 2024.

Food and Drug Administration 98

Food and Drug Administration Medicine Physicians Food 98

European Pharmaceutical Review

DECEMBER 1, 2023

AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx), for a total of approximately $10.1 The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease.

Food and Drug Administration 116

Food and Drug Administration Marketing FDA Food 116

European Pharmaceutical Review

OCTOBER 24, 2024

The biologic treatment was granted approval as Kisunla (donanemab-azbt) in the US by the Food and Drug Administration (FDA) in July 2024. In August 2024, Eisai/Biogen’s anti-Aβ mAb Leqembi (lecanemab) became the first [disease-modifying therapy] to be approved for [Alzheimer’s] in the UK”. billion and $2.0

Food and Drug Administration 52

Food and Drug Administration Side effects Medicine Patients 52

European Pharmaceutical Review

APRIL 17, 2024

The one-year data will be presented at the 2024 American Academy of Neurology (AAN) Annual Meeting. The target decision dates of mid-2024 for the European Medicines Agency (EMA) and September 2024 for the US Food and Drug Administration (FDA) regarding submission of data from the Phase III OCARINA II trial, Roche confirmed.

Food and Drug Administration 93

Food and Drug Administration Safety Medicine Food 93

European Pharmaceutical Review

APRIL 16, 2024

Pre-specified interim analysis results from the Phase III APPLAUSE-IgAN clinical trial were presented at the 2024 World Congress of Nephrology (WCN). In December 2023, the US Food and Drug Administration (FDA) approved the treatment for adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH).

Food and Drug Administration 97

Food and Drug Administration Food Safety Medicine 97

Pharmaceutical Technology

JUNE 6, 2023

The therapy has also received orphan drug designation and breakthrough therapy designation from the US Food and Drug Administration. Alkeus Pharmaceuticals intends to submit a new drug application for gildeuretinol in 2024.

Food and Drug Administration 111

Food and Drug Administration Food Pharmaceutical Medicine 111

European Pharmaceutical Review

APRIL 12, 2024

There has been a “notable” rise in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology for gene therapies over the past five years, according to data and analytics firm GlobalData. These agreements have amassed a total deal value of $21 billion.

Food and Drug Administration 104

Food and Drug Administration Medicine Food Pharmaceutical 104

European Pharmaceutical Review

DECEMBER 22, 2023

Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024. The drug is also undergoing trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease.

Food and Drug Administration 98

Food and Drug Administration Side effects Safety Food 98

European Pharmaceutical Review

NOVEMBER 2, 2023

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). We do not expect entry of Stelara biosimilars in the United States during 2024,” Joseph Wolk CFO, Johnson & Johnson, stated during the company’s Q3 earnings call on 18 October.

Food and Drug Administration 98

Food and Drug Administration FDA Side effects Safety 98

European Pharmaceutical Review

NOVEMBER 28, 2023

The US Food and Drug Administration (FDA) has approved the first drug for desmoid tumours (desmoid fibromatosis), an oral gamma secretase inhibitor. SpringWorks Therapeutics’ Ogsiveo (nirogacestat) tablets are authorised for adults with progressing desmoid tumours who require systemic treatment.

Food and Drug Administration 104

Food and Drug Administration Medicine FDA Food 104

European Pharmaceutical Review

JULY 4, 2024

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few?

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

European Pharmaceutical Review

APRIL 26, 2024

Recent biosimilar developments In February 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for Pyzchiva as a biosimilar to treat the autoimmune condition plaque psoriasis.

Food and Drug Administration 98

Food and Drug Administration Medicine Marketing Food 98

European Pharmaceutical Review

MARCH 14, 2023

Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining Seagen’s antibody -drug conjugate (ADC) technology… with Pfizer’s capabilities and expertise,” shared Dr Albert Bourla, Pfizer Chairman and Chief Executive Officer. billion of revenue in 2023.

Food and Drug Administration 119

Food and Drug Administration Medicine Engineering Food 119

European Pharmaceutical Review

JUNE 13, 2024

In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa. In May 2024, Ocugen announced the second cohort (medium dose) completed dosing in the dose-escalation phase. What’s the latest and what’s next?

Manufacturing 145

Manufacturing Food and Drug Administration Engineering Safety 145

PM360

FEBRUARY 12, 2024

Given that less than 10% of rare diseases currently have an available treatment approved by the United States Food and Drug Administration (FDA) , advocating for the speedy development of novel drugs and therapies is a crucial step in improving the quality of life for those affected. What is a Rare Disease?

Food and Drug Administration 105

Food and Drug Administration Patients Medical Networking 105

European Pharmaceutical Review

AUGUST 26, 2024

Akantior was granted Orphan Drug Designation from the US Food and Drug Administration (FDA) to treat acanthamoeba keratitis. SIFI confirmed that the first commercial launch of the eye drops is planned in Germany in Q4 of 2024.

Food and Drug Administration 69

Food and Drug Administration Food Medicine Patients 69

European Pharmaceutical Review

FEBRUARY 2, 2024

ADUHELM was the “groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the [Alzheimer’s] field,” commented Christopher Viehbacher, President and Chief Executive Officer of Biogen. On 9 January 2024, Eisai confirmed that LEQEMBI was approved in China to treat Alzheimer’s.

Food and Drug Administration 97

Food and Drug Administration FDA Food Marketing 97

European Pharmaceutical Review

MARCH 13, 2024

FDA inspections Identification of data integrity deviations Of the 70 Warning Letters issued by the US Food and Drug Administration (FDA) so far in 2024, three have identified data integrity issues at pharmaceutical manufacturing sites outside the US. In a letter issued to China-based Sichuan Deebio Pharmaceutical Co.

FDA 98

FDA Food and Drug Administration Manufacturing Pharmaceutical manufacturing 98

Legacy MEDSearch

MARCH 1, 2024

Boston Scientific’s AGENT Drug-Coated Balloon (DCB) has been granted approval by the U.S. Food and Drug Administration (FDA) for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ” The final results from AGENT IDE are expected to be presented at CRT 2024.

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Physicians 52

European Pharmaceutical Review

FEBRUARY 8, 2024

Regulatory plans for the cystic fibrosis medicine By mid-2024, Vertex declared that it plans to submit a New Drug Application (NDA) to the US Food and Drug Administration and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in patients with cystic fibrosis aged six years and older.

Food and Drug Administration 98

Food and Drug Administration Medicine Medical Consulting 98

Legacy MEDSearch

MARCH 7, 2024

Food and Drug Administration (FDA) announced the clearance of Dexcom’s device, marking it as the first continuous glucose monitor available over the counter. Dexcom disclosed its plans to make Stelo available for purchase online without the need for a prescription, starting in summer 2024. On March 5, the U.S.

Food and Drug Administration 52

Food and Drug Administration FDA Food Management 52

European Pharmaceutical Review

JANUARY 29, 2024

1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue 2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way to resolution.

Pharmaceutical 111

Pharmaceutical Food and Drug Administration Medicine FDA 111

European Pharmaceutical Review

AUGUST 12, 2024

The deal is anticipated to be finalised in Q3 of 2024. Progress in immunotherapy drug development In June, the US Food and Drug Administration (FDA) authorised an immunotherapy combination to treat endometrial cancer.

Food and Drug Administration 59

Food and Drug Administration Food FDA Patients 59

European Pharmaceutical Review

SEPTEMBER 2, 2024

Three anti-hypertensive drugs combined in low doses into a single pill has been shown to be superior to standard care for lowering blood pressure in patients with uncontrolled hypertension. The oral treatment GMRx2 is biopharma George Medicines’ lead drug candidate.

Food and Drug Administration 59

Food and Drug Administration Medicine Biopharma Food 59

European Pharmaceutical Review

DECEMBER 15, 2023

An approval decision by the European Commission is expected in February 2024. Casgevy was also approved by the US Food and Drug Administration (FDA) for use in patients with sickle cell disease earlier in December.

Medicine 110

Medicine Food and Drug Administration Food Patients 110

Pharmaceutical Technology

APRIL 19, 2023

Neuronascent plans to start a potential Phase II trial of its neurorestorative agent NNI-362 in Parkinson’s disease in H1 2024, said CEO Judith Kelleher-Andersson in an interview with P harmaceutical Technology. But if it proves difficult, the company may be open to potentially licensing the drug, Kelleher-Andersson noted.

Food and Drug Administration 52

Food and Drug Administration Recruitment Prospecting Food 52

Pharmaceutical Technology

MAY 19, 2023

It received approval from the US Food and Drug Administration in October 2018. will be paid in equal quarterly instalments in 2024. Alimera Sciences has acquired the US commercialisation rights for Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg from EyePoint Pharmaceuticals.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Food Sales 52

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has accepted Satsuma Pharmaceuticals’ 505(b)(2) new drug application (NDA) for STS101 for acute treatment of migraine, for review. The prescription drug user fee act (PDUFA) date is expected to be set as January 2024.

Food and Drug Administration 59

Food and Drug Administration FDA Prescription Food 59

European Pharmaceutical Review

JANUARY 8, 2024

Commercial manufacturing of Novartis’ radioligand therapy Pluvicto TM (INN: lutetium ( 177 Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its largest and most advanced manufacturing facility for these treatments manufacturing in the world, has been approved the US Food and Drug Administration (FDA).

FDA 96

FDA Food and Drug Administration Manufacturing Medicine 96

Pharmaceutical Technology

JUNE 13, 2023

The US Food and Drug Administration (FDA) has approved Neobiosis’ investigational new drug (IND) application for ViXome to treat post-Covid-19 syndrome (also known as long Covid). We are eager to confirm our preclinical data in the clinic and expect to begin enrolling patients in Phase I during the second quarter of 2024.”

Food and Drug Administration 59

Food and Drug Administration FDA Food Safety 59